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Abstract 
Purpose: To investigate tigecycline prescription and patient outcomes in the Kingdom of Saudi Arabia 
(KSA).  
Methods: A retrospective observational study was conducted in three KSA government hospitals, 
between January, 2013 and May, 2014. The patients were identified from electronic prescription 
records; data were retrieved by trained researchers.  
Results: Thirty-seven patients who received tigecycline were included (mean age, 52.5 years; range, 
17   92); 51.4 % were female. Tigecycline was prescribed for sepsis (59.5 %), pneumonia (21.6 %), 
and/or intra-abdominal infections (13.5 %). The majority of the patients (86.5 %) were prescribed 
tigecycline in intensive care unit (ICU) and the remaining patients were in the general medical ward. 
APCHE II score at the beginning of treatment was 16.8 ± 4.3, indicating severe disease. Susceptibility 
testing revealed 22 different bacterial pathogens, most commonly Acinetobacter baumannii (20 patients) 
and Klebsiella pneumoniae (14 patients). A significant proportion (56.7 %) was polymicrobial and 16.2 
% involved suspected resistant pathogens. Sixteen patients recovered (5 on tigecycline alone, 5 with 
additional antimicrobials, and six switched to alternatives) while 21 patients died (nine on tigecycline 
alone, 12 with additional antimicrobials).  
Conclusions: The study revealed that tigecycline prescription was conducted according to marketing 
authorizations and national guidelines. Infection severity/stage and comorbidities may influence 
patients’ response, and explain some of the poor outcomes.  
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INTRODUCTION 
 
Bacterial infections present an increasing and 
well-recognized challenge to clinical practice for 
several reasons: the rapid emergence of 
resistant strains [1]; medication over-prescription 
in all healthcare settings [2,3]; and ethical issues, 
for example inappropriate patient demands [4]. 
Furthermore, the empirical antibacterial therapy 
without sufficient intelligence in relation to 
pathogen susceptibility has been linked to 
increased fatality in patients with sepsis [5]. The 
discovery and development of truly novel anti-
bacterials by the pharmaceutical industry has 
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declined markedly, primarily due to scientific 
complexity and resource implications [6]. 
Tigecycline is one of the very few unique agents 
launched in the last decade, with initial 
introduction in the United States (US) in 2005 [7]. 
The US Food and Drug Administration (FDA) 
licensed tigecycline for the treatment of patients 
with skin and soft tissue infections, complicated 
intra-abdominal infections, and community-
acquired pneumonia [8]; followed by the 
European Medicine Agency (EMA) licensing in 
2006 [9]. 
 
Tigecycline circumvents mechanisms of bacterial 
resistance via a modification of the central 
structure of minocycline by the addition of a 9-t-
butyl-glycylamido side chain. This renders 
tigecycline effective against a wide range of 
gram-positive and gram-negative organisms, 
notably highly resistant pathogens such as 
methicillin-resistant Staphylococcus aureus, 
Staphylococcus epidermidis, vancomycin-
resistant Enterococcus species, extended 
spectrum β-lactamase producers (ESBL), 
Clostridium difficile and many carbapenemase-
producing Enterobacteriaceae; however, it has 
no activity against Proteus or Pseudomonas 
species [10,11]. It exhibits a linear 
pharmacokinetic profile, a large volume of 
distribution Vd (7   10 L), a half-life of 37 - 67 h, 
and clearance of 0.2 - 0.3 L/h/kg [12,13]. In 
adults, it is administered intravenously as a 
loading dose of 100 mg, followed by 50 mg every 
12 h, with dose-reduction recommended in cases 
of sever hepatic impairment as in Child-Pugh 
Class C. Adverse drug reactions include: nausea 
(26 %), vomiting (18 %), diarrhea (12 %), 
abdominal pain (6 %), headache (6 %), and 
increased serum glutamic pyruvic transaminase 
levels (< 2 %) [14]. 
 
Two main concerns of tigecycline have become 
apparent recently: the emerging clinical 
resistance [15] and life-threatening adverse 
events [16] which have been confirmed by 
independent meta-analyses of all-cause mortality 
data [17,18]. Studies conducted in Europe [19] 
and Taiwan [20] have demonstrated largely, an 
appropriate use of tigecycline in terms of its 
licensed indications and dosage, highlighting the 
need to balance patients’ risks and benefits.  
 
Tigecycline was introduced to the Saudi market 
in 2008 to treat skin, soft-tissue, and intra-
abdominal infections. In August, 2011, the Saudi 
Food and Drug Authority (SFDA) issued a safety 
notification advising that tigecycline should only 
be prescribed for licensed indications and as a 
last resort, where alternative antimicrobials were 
deemed inappropriate [21].  
METHODS 
 
Study design 
 
A retrospective observational study was 
conducted in several hospitals. This study was 
approved by the Ethical Committee of the 
Ministry of Health Research Centre in Jeddah, 
KSA. All the three hospitals must comply with 
local prescription guidelines for tigecycline: the 
prescription should be initiated by a medical 
consultant; pathogen susceptibilities should be 
determined by laboratory analyses; and the 
prescription should be authorized by an 
infectious diseases physician, a microbiologist, 
and a pharmacist. 
 
Study setting and participants 
 
The study was conducted in three main KSA 
governmental hospitals: King Fahad Hofuf 
Hospital (KFHH); King Fahad Jeddah Hospital 
(KFJH); and King Fahad Specialist Hospital 
(KFSH), located in the regional provinces of 
Makkah, Al-Ahsa, and Qassim, respectively. 
Each hospital has 500-900 beds and mainly 
serves adult patients. All patients prescribed 
tigecycline between January 2013 and May 2014 
were included in the study, with no exclusions.  
 
Data collection and analysis 
 
The patients prescribed tigecycline were 
identified from electronic prescription data. A 
data collection template was developed and 
piloted to record the following: patient 
demographics (age, sex, weight, hospital); past 
medical history; adverse drug reactions, 
allergies, medication history (including current 
medication); reason for admission to hospital 
(signs, symptoms); Acute Physiology and 
Chronic Health Evaluation (APACHE II) disease 
severity score [22]; tigecycline indication and 
regimen (dose, route, duration); documented 
adverse events; renal and hepatic function; 
microbiological analyses of pathogen 
susceptibility; ongoing monitoring (documented 
clinical response); and clinical safety endpoints 
(documented recovery, surgery, readmission). 
The data were entered into SPSS (SPSS Inc., 
Cary, NC version 22.0) and analyzed using 
descriptive statistics. Missing data were recorded 
for all variables considered. Three hospital 
pharmacists attended researcher training 
sessions to receive information about the 
purpose of the research and the data collection 
process. The data were collected from the 
patients’ electronic medical records in KFSH and 
KFHH, and from paper-based medical records in 
Tobaiqy et al 
Trop J Pharm Res, October 2015; 14(10): 1921  
 
KFJH, where electronic records had not been 
fully implemented at the time of this study. 
 
RESULTS 
 
Thirty-seven patients were included: 18 in KFHH; 
11 in KFJH; and 8 in KFBH. The mean patient 
age was 52.5 years (SD ± 21.4, range 17   92) 
and 19 (51.4 %) were female. The demographics 
at the start of tigecycline therapy, disease 
severity scores, and comorbidities, as shown in 
Table 1. Thirty-two patients (86.5 %) were  
 
Table 1: Summary of patients’ characteristics and reasons for tigecycline use 
 
Characteristics All patients Improveda Diedb 
Number of patients 37 (100%) 16 (43.2%) 21 (56.8%) 
Mean Age (SD) 52.5 (21.4) 56.18 (16.37) 52.7 (24.01) 
Women, n (%) 19 (51.4%) 5 (26.3%) 14 (73.7%) 
Comorbidities, n (%) 
HTN  17 (17.3%) 4 (23.5%) 13 (76.5%) 
DM 16 (16.3%) 6 (37.5%) 10 (62.5%) 
Heart (CHF, IHD, MVS, MVR, LVH, LBBB) 13 (13.3%) 3 (23.1 %) 10 (76.9%) 
Renal (ARF, CKD, ESRD, other) 12 (12.3%) 3 (25%) 9 (75%) 
Old CVA 6 (6.2%) 1 (16.7%) 5 (83.3%) 
Other (amputated leg, bed-ridden, psychosis, 
piles, thrombocytopenia, warfarin overdose) 6 (6.2%) 2 (33.3%) 4 (66.6%) 
Neurological (brain atrophy, multiple brain 
contusions, PD, CP) 4 (4.1%) 2 (50%) 2 (50%) 
ASP 4 (4.1%) 1 (25%) 3 (75%) 
Epilepsy 3 (3.1 %) 2 (66.6%) 1 (33.3%) 
Respiratory (asthma, COPD, IPF) 3 (3.1 %) 1 (33.3%) 2 (66.6%) 
PE 2 (2.0%) - 2 (100%) 
MR 2 (2.0%) - 2 (100%) 
SCA 2 (2.0%) - 2 (100%) 
Muscular (DMD, rhabdomyolysis) 2 (2.0%) 1 (50%) 1 (50%) 
Autoimmune/inflammatory (RA, SLE) 2 (2.0%) 1 (50%) 1 (50%) 
Infectious (TB, HCV) 2 (2.0%) - 2 (100%) 
Vascular (DIC) 1 (1.0%) 1 (100%) - 
Cancer 1 (1.0%) 1 (100%) - 
Severity/organ dysfunction scores 
APACHE II score, n 43 11.3 31.7 
mean ± standard deviation (range) 16.8 ± 4.3 (0-28) 8.7 ± 5.5 (0-11) 
22.1 ± 7.6 
(4-28) 
≤ 15, n (%) 11 (25.6) 7 (61.9) 5 (15.8) 
≤ 15, mean (median) 7 (8.8) 12.4 (13.7) 11.6 (14.3) 
> 15, n (%) 23 (67.6) 3 (8.8) 20 (58.8) 
> 15, mean (median) 8.3 (9.7) 11.1 (12.6) 16.1 (18.4) 
missing/unknown, n 3 1 2 
Reasons for tigecycline use, alone or in combination, in all patients 
Reason, n (%)c 
Failure of previous therapyd 5 (13.5%) 1 (20%) 4 (80%) 
Suspected resistant pathogens 6 (16.2%) 3 (50%) 3 (50%) 
Need broad-spectrum coverage/polymicrobial 
infection 21 (56.7%) 9 (42.9%) 12 (57.1%) 
Allergy to/intolerance of previous antibacterial 2 (5.4%) 1 (50%) 1 (50%) 
Renal impairment 3 (8.1%) 2 (66.7%) 1 (33.3%) 
Others NA - - 
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation score; ARF, acute renal failure; 
ASP, aspiration pneumonia; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic 
obstructive pulmonary disease; CP, cerebral palsy’ DIC, disseminated intravascular coagulopathy; DM, diabetes 
mellitus; DMD, Duchenne muscular dystrophy; ESRD, end-stage renal disease; HTN, hypertension; HCV, 
hepatitis C virus; IHD, ischemic heart disease; IPF, interstitial pulmonary fibrosis; LBBB, left bundle branch block; 
LVH, left ventricular hypertrophy; MR, mental retardation; MVR, mitral valve stenosis; MVS, mitral valve 
regurgitation; NA, not available; PD, Parkinson’s disease; PE, pulmonary edema; RA, rheumatoid arthritis; SCA, 
sickle-cell disease; SLE, systemic lupus erythematosus; TB, tuberculosis. aImprovement was defined as a clinical 
cure or response without additional antibiotic. bDeath was defined as failure or no improvement with additional 
antibiotic. cPatients could have more than one reason. dPrevious therapy included all treatments that were given 
prior to tigecycline 
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Figure 1: Treatment and outcomes of patients prescribed tigecycline (n = 37) 
 
Table 2: Tigecycline indications (n = 37) 
 
Indication % patients 
Sepsis 59.5 
Community-acquired bacterial pneumonia 21.6 
Intra-abdominal infection 13.5 
Suspected community-acquired bacterial pneumonia 10.8 
Wound infections (abscess, gangrene, diabetic foot and bed sores) 10.8 
Urinary tract infection 2.7 
Cystic fibrosis 2.7 
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Table 3: Identified bacterial pathogens (n = 74) 
 
Gram-positive pathogens n 
Enterococcus faecalis 3 
Staphylococcus aureus 1 
Staphylococcus epidermidis 1 
Methicillin-resistant Staphylococcus aureus 1 
Streptococcus anginosus 1 
Staphylococcus saprophyticus 1 
Viridans streptococci 1 
Gram-negative pathogens  
Acinetobacter baumannii 20, 3 resistant 
Klebsiella pneumonia 14 
Pseudomonas aeruginosa 11, 2 resistant 
Escherichia coli 4, 2 resistant 
Proteus mirabilis 4 
ESBL-producing Enterobacteriaceae 3 
Serratia marcescens 2 
Providencia stuartii 1 
Morganella morganii 1 
ESBL-producing Klebsiella pneumoniae 1 
Klebsiella oxytoca 1 
Enterobacter cloacae 1 
Pseudomonas luteola 1 
Citrobacter freundii 1 
 
treated with tigecycline in the intensive care unit 
(ICU) and the remaining proportion of patients 
were in the medical wards. Biochemical 
monitoring prior to commencing tigecycline, 
identified three patients with impaired renal 
function; there was no evidence of impaired 
hepatic function. 
 
The documented indications for tigecycline are 
given in Table 2, with some patients having more 
than one indication. None of the patients had 
been treated previously for similar infections. 
 
DISCUSSION 
 
Tigecycline is a very few unique antimicrobial 
agents which was launched in the last decade, 
with initial introduction to the US in 2005. Two 
main concerns of tigecycline have become 
apparent since its launch; emerging clinical 
resistance and life-threatening adverse events. 
Tigecycline was introduced to the KSA market in 
2008. 
  
This study showed that tigecycline prescription 
patterns within these hospitals in the KSA were 
mostly in line with the guidelines [7,9]; it was 
reserved and prescribed for clearly defined 
indications at appropriate initiation and 
maintenance doses[7,11,22]. This is in line with 
the previous studies in Taiwan [19] and Europe 
[20]. Tigecycline was initiated under the 
instruction of a consultant in according to the 
recommended dosing schedule of 100 mg 
intravenously initially, followed by 50 mg every 
12 hours (except one patient with renal 
insufficiency received 50 mg followed by 25 mg 
every 12 h). The treatments and patients’ 
outcomes are shown in Figure 1. 
 
However, we identified tigecycline usage for 
some unapproved indications that both the SFDA 
and FDA have issued warnings against; these 
included diabetic foot, urinary tract infections, 
undefined pneumonia, and septic shock.  
 
These dangerous pathogens are acknowledged 
to pose the greatest therapeutic challenges and, 
while often drug-resistant, may respond to 
tigecycline [23,24]. Other studies in the KSA 
reported that 20 % of Acinetobacter baumannii 
cases showed an increased resistance in 2011, 
as compared to 10 % in 2010 [25,26]. A range of 
pathogens were isolated, reflecting the 
complexity of the required therapeutic plans. 
Interestingly, tigecycline was also effective in 
patients infected with Serratia marcescens, 
previously reported to be resistant to tigecycline 
[27], and similarly in a patient infected with 
Klebsiella pneumoniae [28,29].  
 
Of the 37 patients prescribed tigecycline, 16 
recovered (five on tigecycline alone, five with 
additional antimicrobials, and six who switched to 
alternatives) and 21 died, 14 were confirmed with 
Klebsiella pneumonia, (nine on tigecycline alone, 
twelve with additional antimicrobials). In 2011, 
the SFDA warned of a high death risk if 
tigecycline is used for pneumonia, or any 
unapproved indications [21]. A further 
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confirmation by the FDA was released in 2013 
warning against the increased risk of death in 
approved and unapproved indications, stating 
that tigecycline should only be used when 
necessary [16]. Ten out of the 16 patients, 
continued on tigecycline therapy, and the other 6 
were changed to other antibiotics because 
tigecycline therapy had failed and/or resistant 
pathogens were present. In the ten recovered 
patients who continued on tigecycline, 
improvement was documented as occurring 
within two to seven days, with full recovery 
observed between six and 22 days.  
 
Tigecycline's adverse events include: nausea 
and vomiting (n = 4); diarrhea (n = 2); and 
hypotension (n = 1). These mostly appeared on 
the first or second day of tigecycline treatment. 
None of these adverse drug reactions led to 
tigecycline discontinuation or treatment change. 
Patients’ clinical outcomes varied and were 
extremely difficult to associate with tigecycline 
efficacy because of the influences of confounding 
factors, including severity and stage of infection, 
comorbidities, and concurrent antimicrobial 
therapy. The documented adverse events were 
 
Table 4: Indication, treatment, and outcomes of patients commenced and continued on tigecycline (n = 10) 
  
Documented 
indication(s)   
Pathogen(s) Antimicrobials 
added to tigecycline 
Days to 
documented 
symptom 
improvement 
Days to 
documented 
recovery 
Severe 
pneumonia 
Klebsiella 
pneumoniae 
Vancomycin, 
amikacin, 
meropenem, 
ribavirin, and 
interferon α-2an 
5 7 
Intra-abdominal 
infection 
Acinetobacter 
baumannii, 
Escherichia 
coli 
Meropenem and 
caspofungin 
6 22 
Septic shock, 
bilateral 
pneumonia 
Serratia 
marcescens 
No 7 14 
Acute 
respiratory 
failure with CO2 
narcosis 
Multi-drug 
resistant 
Acinetobacter 
baumannii 
No 7 14 
Interstitial 
pulmonary 
fibrosis, septic 
shock 
Proteus 
mirabilis, 
Acinetobacter 
baumannii, 
Pseudomonas 
aeruginosa 
No 5 8 
Pneumonia Providencia 
stuartii, 
Serratia 
marcescens 
No 5 8 
Diabetic foot 
infection 
Acinetobacter 
baumannii, 
Escherichia 
coli 
Meropenem and 
metronidazole 
2 22 
Fever, malignant 
neoplasm of the 
nasopharynx 
Coagulase-
negative 
Staphylococci, 
non-albicans 
Candida 
Colistin 3 6 
Urinary tract 
infection, bed 
sores 
Morganella 
morganii, 
Klebsiella 
oxytoca 
Amikacin 5 12 
Septic shock, 
catheter-related 
Multi-drug 
resistant 
Acinetobacter 
baumannii 
No 4 7 
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of low prevalence and severity, and were similar 
to those reported previously [6,14]. While life-
threatening adverse events have been noted with 
tigecycline [16,18] and have resulted in safety 
warnings, it is unlikely that the high mortality 
observed in this study was directly attributable to 
tigecycline. Many patients included in this study 
died, irrespective of treatment, and few patients 
continued on tigecycline as the sole 
antimicrobial.  
 
Limitations of the study 
 
The small dataset and the potential reporting 
bias due to the reliance on case notes; are the 
major two limitations. It is possible that drug 
adverse events were underreported. Even when 
tigecycline is mostly prescribed in line with the 
relevant marketing authorizations, patient 
outcomes are complex and influenced by many 
confounding factors and may not necessarily be 
generalizable to the entire KSA.  
 
CONCLUSION 
 
The study revealed that tigecycline prescription 
was in line with the marketing authorizations and 
national guidelines. While many patients had 
poor outcomes, these could not be attributed 
solely to a lack of tigecycline efficacy or toxicity; 
confounding factors, including infection 
severity/stage and comorbidities may influence 
patients’ outcomes. 
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